EY
EyePoint Pharmaceuticals, Inc.
EYPT · NASDAQ
$4.56 +0.00% (+$0.00)
1M -64.96%
Market Cap $384.0M
P/E Ratio -
Div. Yield -
ROE 135.81%
Piotroski F-Score Weak
2/9Valuation
40 /100
Fair P/B 2.31x
P/S 137.68x
EV/EBITDA N/A
Growth
22 /100
Declining Book val. growth 47.00%
Rev. growth 8.83%
FCF growth N/A
Profitability
17 /100
Weak Net margin 10,994.70%
Op. margin 11,365.20%
FCF margin 9,726.75%
Quality
0 /100
Poor ROE 135.81%
ROA 134.38%
Asset turnover 0.01x
Debt
100 /100
Low Current ratio 4.50x
Debt/Equity 0.13x
Net debt/EBITDA N/A
Stability
37 /100
Moderate Rev. volatility 19.37%
EPS volatility 38.17%
Profitable years 0
Bulios Scoring descrie calitatea și istoricul unei companii, nu randamentul viitor. Un scor ridicat nu este un semnal de cumpărare. Află mai multe
Întreabă StockBot despre EYPT
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Jay S. Duker
Employees
214
Headquarters
Watertown
Evenimente viitoare
04 NOV.
Earnings
Upcoming earnings report